Product Images Sunitinib Malate
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 9 images provide visual information about the product associated with Sunitinib Malate NDC 16714-678 by Northstar Rxllc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
SPL-Sunitinib-Northstar-12.5 mg label - SPL Sunitinib Northstar 12.5 mg label
This text is not readable.*
SPL-Sunitinib-Northstar-25 mg label - SPL Sunitinib Northstar 25 mg label
SPL-Sunitinib-Northstar-37.5 mg label - SPL Sunitinib Northstar 37.5 mg label
SPL-Sunitinib-Northstar-50 mg label - SPL Sunitinib Northstar 50 mg label
SPL-Sunitinib-Northstar-Figure-1 - SPL Sunitinib Northstar Figure 1
This is a clinical trial study comparing the effect of Sunitinib versus Placebo on Time to Tumor Progression. The study included 207 participants given Sunitinib and 105 given Placebo. Median time to tumor progression was 27.3 weeks for Sunitinib versus 6.4 weeks for Placebo. Hazard ratio was 0.33 (95% CI 0.23 to 0.47) with a significant p-value of <0.0001. The time frame for the study was in weeks.*
SPL-Sunitinib-Northstar-Figure-2 - SPL Sunitinib Northstar Figure 2
The text is providing a comparison of Sumitinib and IFN-a drugs for Progression Free Survival Probability (%). It includes the number of subjects in each group, their median weeks, hazard ratio, and CI values. The text also shows a graph representing the percentage of survival probability over time in both groups.*
SPL-Sunitinib-Northstar-Figure-4 - SPL Sunitinib Northstar Figure 4
This text is a statistical analysis of a medical study comparing the effectiveness of the drug Sunitinib versus a placebo in terms of progression-free survival in patients. It includes survival probabilities, hazard ratios, and median survival times for both groups, as well as a graph showing the number of subjects at risk over time.*
SPL-Sunitinib-Northstar-Molecular structure - SPL Sunitinib Northstar Molecular structure
SPL-Sunitinib-Northstar-figure 3 - SPL Sunitinib Northstar figure 3
This is a graph with Disease-Free Survival Probability (%) on the y-axis and Time (Years) on the x-axis, with hazard ratio equal to 0.76. The graph compares two groups, Sunitinib and Placebo, based on the number of subjects at risk over a duration of 10 years. The P-value is 0.03.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.